Anti-Human CD3 x DLL3 (Tarlatamab) (C3320-1.0mg)

Anti-Human CD3 x DLL3 is a bispecific T-cell engager (BiTE) designed to target CD3 on T- cells and Delta-like ligand 3 (DLL3) on tumor cells. DLL3 is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, making it an attractive target for immunotherapy. By redirecting T-cells to attack DLL3-expressing tumor cells, this bispecific antibody offers a novel treatment approach for SCLC, a disease known for its poor prognosis and limited therapeutic options. Preclinical studies have demonstrated that DLL3/CD3 bispecific antibodies can induce potent, DLL3-dependent T-cell-mediated lysis of tumor cells, recruit T-cells into non-inflamed tumor tissues, and lead to tumor regression in animal models. While specific efficacy data for this antibody are not provided, BiTE antibodies have generally shown high potency, with some studies indicating efficacy at sub-picomolar concentrations.1-3. AMG757, also known as Tarlatamab, is a promising example of a bispecific T-cell engager targeting DLL3 and CD3 for SCLC treatment. Studies have shown that AMG757 induces potent tumor lysis and T-cell activation, resulting in significant tumor regression and even complete responses in preclinical models. Clinical trials have reported manageable safety profiles with encouraging response durability, including objective response rates of 23.4% to 40% and disease control rates of 51.4%. Notably, AMG757 has demonstrated antitumor activity with durable responses and promising survival outcomes in patients with previously treated SCLC, making it a viable option for targeting DLL3-expressing tumors4-6.